search
Back to results

Cerebellar tDCS and Balance Training in PwMS

Primary Purpose

Multiple Sclerosis

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Sham Transcranial Direct Current Stimulation (tDCS)
Balance Training
2 mA Transcranial Direct Current Stimulation
4 mA Transcranial Direct Current Stimulation
Sponsored by
University of Iowa
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Multiple Sclerosis focused on measuring Brain Stimulation, Balance Training

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. medically diagnosed with relasping-remitting multiple sclerosis
  2. 18-70 years of age
  3. moderate disability (score of 2-6 on the Patient Determined Disease Scale [PPDS])
  4. self-reported differences in function between legs, have fallen within the last year
  5. able to walk for 6 mins, and not taking any psychoactive medication.

Exclusion Criteria:

  1. relapse within the last 60 days
  2. have changed disease modifying medications in the last 45 days
  3. are currently pregnant
  4. have a concurrent neurological or neuromuscular disease
  5. have been hospitalized within the last 90 days
  6. have any contraindications for the tDCS device (i.e., pacemakers or metal implants)
  7. are unable to understand/sign the consent form.

Sites / Locations

  • University of Iowa

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Sham Comparator

Experimental

Experimental

Arm Label

Sham tDCS

2 mA tDCS

4 mA tDCS

Arm Description

The tDCS device will perform a 30 second ramp up to 2 mA and then an immediate 30 second ramp down to 0 mA. Until the 19:30 minute time point, the tDCS will remain at 0 mA. At this time point, the tDCS will ramp up to 2 mA and then will immediately ramp back down to 0 mA.

The participants in this group will receive tDCS at 2 mA while seated comfortably. The intensity will start at 0 mA and will be incrementally increased to the target intensity (2 mA) over the initial 30 seconds. Then, the tDCS will deliver stimulation at the target intensity until the 19:30 minute time point. At this point, the current will gradually decrease back to 0 mA.

The participants in this group will receive tDCS at 4 mA while seated comfortably. The intensity will start at 0 mA and will be incrementally increased to the target intensity (4 mA) over the initial 30 seconds. Then, the tDCS will deliver stimulation at the target intensity until the 19:30 minute time point. At this point, the current will gradually decrease back to 0 mA.

Outcomes

Primary Outcome Measures

Score on the Berg Balance Scale
Assess balance and fall risk in adults
Time to complete the Timed Up and Go Test (TUG)
Stand up from a seated position, walk to a marker

Secondary Outcome Measures

Outcomes on Electromyography (EMG)
Investigation of muscle activation strategies during balance and walking tasks
Time to complete the Six Minute Walk Test (6MWT)
Walk back and forth between two markers spaced 30 meters apart for 6 minutes.
Score on the Fatigue Severity Scale (FSS)
Scale that examines the severity of fatigue and the impact on the participant's activities. There are nine statements about the participant's fatigue over the last week. They are asked to rate the severity on a scale from 1 to 7 (1 disagree, 7 agree) for each question.
Outcomes on Static Posturography
Measures postural control
Score on Patient Determined Disease Steps (PDDS)
Questionnaire to determine self-reported disability in people with multiple sclerosis. People are asked to choose one out of nine options that best describes how well they walk. 0 is "normal" and 8 is "bedridden."

Full Information

First Posted
May 12, 2020
Last Updated
October 2, 2023
Sponsor
University of Iowa
search

1. Study Identification

Unique Protocol Identification Number
NCT04391023
Brief Title
Cerebellar tDCS and Balance Training in PwMS
Official Title
The Effects of 2 mA and 4 mA Cerebellar Transcranial Direct Current Stimulation and Balance Training to Reduce Fall Risk in People With Multiple Sclerosis
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Completed
Study Start Date
September 26, 2022 (Actual)
Primary Completion Date
July 16, 2023 (Actual)
Study Completion Date
July 16, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Iowa

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
Many people with multiple sclerosis (PwMS) have decreased balance and postural control, gait deficits, and a high frequency of falls. High fall rates and mobility impairments pose a significant risk to the independence and quality of life of PwMS. Therefore, effective interventions to improve balance and postural control are urgently needed to decrease the frequency of falls in PwMS. Balance training has been demonstrated to significantly improve postural control and gait in PwMS. One possible treatment modality to amplify the effects of balance training is transcranial direct current stimulation (tDCS), a non-invasive means to increase cortical excitability and potentially prime the brain for task specific learning. The cerebellum plays a vital role in balance and posture and may be an important target structure for tDCS studies seeking to reduce fall risk. Studies have shown that anodal cerebellar tDCS is effective in improving balance control in older adults with high fall risk and patients with chronic stroke. However, the most effective tDCS intensity and the duration of the effects on balance control has not been established. Moreover, no study has combined cerebellar tDCS and balance training to reduce fall risk in PwMS. The purpose of this study is to investigate the effects of cerebellar transcranial direct current stimulation (tDCS) on fall risk in people with relasping-remitting multiple sclerosis. We will conduct tDCS or SHAM followed by balance training on 4 consecutive days. We will evaluate fall risk with well-established functional tasks, such as the Berg Balance Scale, Timed Up and Go (TUG), the six minute walk test (6MWT), and static posturography. Prospective participants, men and women with relasping-remitting MS, will be recruited. To accomplish this study, 30 participants will be randomly assigned into 3 groups (2 mA tDCS, 4 mA tDCS, or SHAM). This study involves 4 daily visits at the Integrative Neurophysiology Lab at the same time of day for each subject and three follow-up visits. The duration of visit 1 will be approximately 2.5 hours and the duration of visits 2-4 will be approximately 1.5 hours. Visit 5, 6, and 7 will be approximately 24 hours, 1 week, and 3 weeks, respectively, after visit 4 and will last approximately 1.5 hours. During tDCS sessions, participants will undergo either Sham, 2 mA, and 4 mA tDCS for 20 minutes followed by balance training.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Sclerosis
Keywords
Brain Stimulation, Balance Training

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
14 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sham tDCS
Arm Type
Sham Comparator
Arm Description
The tDCS device will perform a 30 second ramp up to 2 mA and then an immediate 30 second ramp down to 0 mA. Until the 19:30 minute time point, the tDCS will remain at 0 mA. At this time point, the tDCS will ramp up to 2 mA and then will immediately ramp back down to 0 mA.
Arm Title
2 mA tDCS
Arm Type
Experimental
Arm Description
The participants in this group will receive tDCS at 2 mA while seated comfortably. The intensity will start at 0 mA and will be incrementally increased to the target intensity (2 mA) over the initial 30 seconds. Then, the tDCS will deliver stimulation at the target intensity until the 19:30 minute time point. At this point, the current will gradually decrease back to 0 mA.
Arm Title
4 mA tDCS
Arm Type
Experimental
Arm Description
The participants in this group will receive tDCS at 4 mA while seated comfortably. The intensity will start at 0 mA and will be incrementally increased to the target intensity (4 mA) over the initial 30 seconds. Then, the tDCS will deliver stimulation at the target intensity until the 19:30 minute time point. At this point, the current will gradually decrease back to 0 mA.
Intervention Type
Device
Intervention Name(s)
Sham Transcranial Direct Current Stimulation (tDCS)
Other Intervention Name(s)
tDCS
Intervention Description
tDCS is a non-invasive brain stimulation technique in which a very weak electrical current (2 mA) is applied to the scalp at the beginning of the session and then remains at 0 mA for the duration of the session to control for placebo-like effects. The anode and cathode will both be placed over the cerebellum.
Intervention Type
Behavioral
Intervention Name(s)
Balance Training
Intervention Description
The balance training protocol will include balance training exercises on both compliant (i.e., foam pad and trampoline) and firm surfaces.
Intervention Type
Device
Intervention Name(s)
2 mA Transcranial Direct Current Stimulation
Other Intervention Name(s)
tDCS
Intervention Description
tDCS is a non-invasive brain stimulation technique in which very weak electrical current (2 mA) is applied to the scalp for 20 minutes. The anode and cathode will both be placed over the cerebellum.
Intervention Type
Device
Intervention Name(s)
4 mA Transcranial Direct Current Stimulation
Other Intervention Name(s)
tDCS
Intervention Description
tDCS is a non-invasive brain stimulation technique in which very weak electrical current (4 mA) is applied to the scalp for 20 minutes. The anode and cathode will both be placed over the cerebellum.
Primary Outcome Measure Information:
Title
Score on the Berg Balance Scale
Description
Assess balance and fall risk in adults
Time Frame
Through study completion, up to 6 months.
Title
Time to complete the Timed Up and Go Test (TUG)
Description
Stand up from a seated position, walk to a marker
Time Frame
Through study completion, up to 6 months.
Secondary Outcome Measure Information:
Title
Outcomes on Electromyography (EMG)
Description
Investigation of muscle activation strategies during balance and walking tasks
Time Frame
Through study completion, up to 6 months.
Title
Time to complete the Six Minute Walk Test (6MWT)
Description
Walk back and forth between two markers spaced 30 meters apart for 6 minutes.
Time Frame
Through study completion, up to 6 months.
Title
Score on the Fatigue Severity Scale (FSS)
Description
Scale that examines the severity of fatigue and the impact on the participant's activities. There are nine statements about the participant's fatigue over the last week. They are asked to rate the severity on a scale from 1 to 7 (1 disagree, 7 agree) for each question.
Time Frame
Through study completion, up to 6 months.
Title
Outcomes on Static Posturography
Description
Measures postural control
Time Frame
Through study completion, up to 6 months.
Title
Score on Patient Determined Disease Steps (PDDS)
Description
Questionnaire to determine self-reported disability in people with multiple sclerosis. People are asked to choose one out of nine options that best describes how well they walk. 0 is "normal" and 8 is "bedridden."
Time Frame
Through study completion, up to 6 months.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: medically diagnosed with relasping-remitting multiple sclerosis 18-70 years of age moderate disability (score of 2-6 on the Patient Determined Disease Scale [PPDS]) self-reported differences in function between legs, have fallen within the last year able to walk for 6 mins, and not taking any psychoactive medication. Exclusion Criteria: relapse within the last 60 days have changed disease modifying medications in the last 45 days are currently pregnant have a concurrent neurological or neuromuscular disease have been hospitalized within the last 90 days have any contraindications for the tDCS device (i.e., pacemakers or metal implants) are unable to understand/sign the consent form.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexandra Fietsam, M.S.
Organizational Affiliation
University of Iowa
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Iowa
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Cerebellar tDCS and Balance Training in PwMS

We'll reach out to this number within 24 hrs